spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  FUZEON 

 HSMN NewsFeed - 29 Dec 2009
Trimeris Announces That Arigene Intends to Terminate Tender Offer
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jan 2008
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 15 Nov 2007
Trimeris Appoints Martin A. Mattingly as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2007
Bioject Announces Roche and Trimeris Update on the Use of Fuzeon(R) with Biojector(R) 2000
Biopharmaceuticals HIV/AIDS Drug Delivery
 HSMN NewsFeed - 3 Oct 2007
Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R)
Biopharmaceuticals HIV/AIDS Drug Delivery
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 10 Apr 2007
Phase Bioscience Strengthens Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2007
Trimeris Announces Management Changes
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 15 Mar 2007
Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2007
Trimeris Reports 2006 FUZEON Sales Results
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2006
Roche and Trimeris Provide Update on Development of Needle-Free Administration for FUZEON(R)
Biopharmaceuticals Drug Delivery HIV/AIDS
 HSMN NewsFeed - 11 Oct 2006
Trimeris Adjusts 2006 FUZEON North American Sales Guidance
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Oct 2006
New Data Show Unprecedented Undetectable Rates of over 90 Percent in HIV Patients Receiving FUZEON(R) and Investigational Integrase Inhibitor MK-0518
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 14 Aug 2006
New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Jun 2006
New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 17 Jan 2006
Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 33 additional stories matching:
FUZEON
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.